Skip to main content
Edwards Lifesciences Logo
Edwards Lifesciences Logo

The JOURNEY trial

Now enrolling

The JOURNEY trial hcp
About the JOURNEY trial

About the trial

About the JOURNEY trial

The JOURNEY trial will assess the safety and efficacy of the J-Valve transfemoral (TF) system in patients with symptomatic, severe (grade 3 or 4), native AR and AR-dominant mixed aortic valve disease, who are judged by a multidisciplinary heart team to be at high risk for open SAVR.

Contact our Patient Support Center to find a participating hospital near you

Aortic regurgitation

Aortic regurgitation

Aortic regurgitation (AR) occurs in approximately 0.4% of all adults, in 1% of individuals aged 65-74 years and 2% of individuals over 70 years of age.1 

Symptomatic patients with chronic severe AR have a poor prognosis and should therefore undergo surgical aortic valve replacement (SAVR) per current guidelines. The guideline directed indications for patients with Grade 3 or 4 AR include these symptomatic patients as well as asymptomatic patients with evidence of left ventricular remodeling, including dysfunction.2,3 

Aortic regurgitation

Trial design

Trial design

*Multimodality diagnostic assessment to determine AR severity by echocardiography and cardiac magnetic resonance (CMR) criteria for indeterminate AR 

Eligibility criteria

  1. Symptomatic according to New York Heart Association (NYHA) functional class (FC) II or higher 
  2. Severe AR, defined as follows (Either A or B):
    • A. Severe AR by Echocardiography (grade 3 or 4)
    • B. Indeterminate AR, in addition to ANY ONE of the following:
      • Cardiac magnetic resonance imaging (CMR)-derived aortic regurgitant fraction (RF) ≥43%
      • CMR-derived RF ≥33% + left ventricular dilation (left ventricular end diastolic volume index (LVEDVi) >105 mL/m2 for men or LVEDVi > 96 mL/m2 for women)
      • CMR-derived RF ≥33% + LV ejection fraction (LVEF) ≤55% or left-ventricular end-systolic volume index (LVESVi) ≥43 mL/m²
  3.  Patient is judged by a multidisciplinary heart team to be at high risk for surgery
  4. Patient has suitable anatomy to accommodate the insertion and delivery of the J-Valve TF System 

Study device

Edwards J-Valve TAVR-AR System

Study device
  1. 1
    Bovine pericardium leaflets
  2. 2
    Interconnecting suture
  3. 3
    Nitinol frame
  4. 4
    Anchor ring
  5. 5
    Latch (attachment to delivery device (x3))
  6. 6
    Grip feature (x6)
Study device

The J-Valve TAVR-AR system procedural animation

‌
contact us lady

We're here for you

We are committed to providing the highest levels of customer service to help our patients improve their quality of life. For any questions, please contact the Edwards Patient Support Center. 

For details about the trial, visit NCT06455787 at Clinical Trials.gov.

Give us a call

888.713.1564

Send us an email

References

  1. Nkomo, V., Gardin, J., Skelton, T., Gottdiener, J., Scott CG, & Enriquez-Sarano, M. (2006, Sep 16). Burden of valvular heart diseases: a population-based study. Lancet, 1005-11. doi:10.1016/s0140-6736(06)69208-8
  2. Otto, C., Nishimura, R., & Bonow, R. (2021). 2020 ACC/AHA Guideline for Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Join Committee on Clinical Practice Guidelines. Circulation, 143(5), e72-e227. doi:10.1161/CIR.0000000000000923
  3. Vahanian , A., Beyersdorf , F., & Praz, F. (2021). 2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease: Developed by the Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 43(7), 5610632. doi:10.1093/eurheartj/ehab395
CAUTION: INVESTIGATIONAL DEVICE.

CAUTION: INVESTIGATIONAL DEVICE.

Limited by Federal (USA) law to investigational use only.